Product logins

Find logins to all Clarivate products below.


Cecilia Klein, PhD

Director for Discovery and Translational Science Consulting

As Global Lead for Clarivate Discovery and Translational Science Consulting Services, Cecilia leads a team of consultants with in-depth knowledge in statistical and machine learning techniques, network, image and multi-OMICs data analysis. They support pharma and biotech customers in the drug discovery process through target and biomarker identification, understanding mechanisms of pathology or drug action and prioritizing candidates for drug repurposing.

Cecilia is expert at making the complex simple and actionable in a timely manner. Her focus is on helping scientists improve decision making and accelerate execution in the area of drug discovery.

Over the past 10+ years working as a computational biologist, she has dealt with virtually every flavor of NGS technologies at every stage of the experimental process: from experimental design through data acquisition to analysis, visualization and interpretation of the results.

Prior to joining Clarivate in 2019, Cecilia completed her PhD in Bioinformatics at the University of Lyon (France) and her Masters in Computational Biology at the National Laboratory of Scientific Computing (Rio de Janeiro, Brazil). She received her Bachelors Degree in Biology from the Federal University of Rio Grande do Sul. She speaks five languages: Portuguese, Spanish, French, English and Catalan. She is also learning Japanese.


arrow_forward
Get in touch with Cecilia

Latest news

News June 17, 2026
Clarivate Releases Journal Citation Reports 2026

Advancing transparency and responsible journal evaluation London, U.K. June 17 2026 — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the release of the Journal…

Partner news June 16, 2026
U.S. News Unveils 2026-2027 Best Global Universities Rankings

Universities in more than 100 countries are evaluated in the newest edition. Washington, D.C. – June 16, 2026 – U.S. News & World Report, the global authority in education rankings…

Partner news
News June 15, 2026
Clarivate’s IPfolio Selected by Mitsubishi Fuso

Managing intellectual property more efficiently with leading data and expertise London, U.K. June 15, 2026. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Mitsubishi…

Related resources

Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization